glp 1 mash approval The FDA has approved Wegovy (semaglutide) as a treatment for metabolic-associated steatohepatitis (MASH) with moderate-to-advanced scarring, a serious liver condition affecting approximately 6% of US adults. Key highlights of drug development program Novo Nordisk's Wegovy gets accelerated

Whether theyre appropriate for you depends on what condition theyre being used to treat, your medical history, the side effects they can cause, and other factors

Detailed results will be presented at the European Association for the Study of Diabetes (EASD) Annual Meeting next month and submitted for publication in a peer-reviewed journal

, ,

Scientific World Journal , 2014, 114

Carnitine palmitoyltransferase I in human carcinomas: a novel role in histone deacetylation

Originally developed for managing type 2 diabetes, clinical trials revealed its profound ability to help patientseven those without diabeteslose significant body weight